Dr Paula Lam is a bioscience industry veteran and currently operates as the Head of Research and Development at CellVec Pte. Ltd, Singapore. Her research involves exploring various strategies to increase the capacity for viral vector production and establish in-house assays for the functional characterization of these viral vectors in various immune cells. 

Dr Lam started her early career as a principal investigator at the National Cancer Center in Singapore while parallelly providing lectures and supervision to postgraduate and graduate students at the National University of Singapore. 

She currently serves as the International Committee Member of the American Society of Gene and Cell Therapy, as well as the local subject expert for viral vector biosafety evaluation. Dr Lam has published over 50 peer-reviewed original articles, book chapters and serves as the editorial reviewer for reputable journals.

Dr Lam holds a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds (UK) and received her post-doctoral fellowship trainings at St Jude Children’s Research Hospital (USA) and The Chinese University of Hong Kong (HK). Following which, she was involved in projects developing optimal gene therapy strategies for brain tumors at Massachusetts General Hospital (USA) under the mentorship of Prof Xandra Breakefield.